Journal article

NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8 T-Cell-Mediated Immunity and Protection against NY-ESO-1 Tumors

E Maraskovsky

Clinical Cancer Research | American Association for Cancer Research (AACR) | Published : 2004

University of Melbourne Researchers

Citation metrics